Kang YK, Yook JH, Park YK, et al. - In the phase III PRODIGY study, it was investigated if neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 could result in improved results vs standard treatment in Korean patients having resectable locally advanced gastric cancer (LAGC). Eligible patients were randomized to D2 surgery followed by adjuvant S-1 (SC group) or neoadjuvant DOS prior to D2 surgery, followed by adjuvant S-1 (CSC group). An improved progression-free survival was conferred by CSC vs SC. Findings of PRODIGY demonstrated effectiveness as well as tolerability of neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, among Korean patients suffering from LAGC.